Showing results (241-250 of 319) with videos related to
Sort By:
Pageof 32
Cancer Research and Treatment|June 19, 2019
Behaviors and Attitudes toward the Use of Complementary and Alternative Medicine among Korean Cancer PatientsJung Hye Kwon, Sang-Cheol Lee, Myung Ah Lee, et al.Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|August 7, 2021
Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061Eric Van Cutsem, Mayur Amonkar, Charles S Fuchs, et al.Journal of Hepatology|August 19, 2020
Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinomaChang Gon Kim, Chan Kim, Sang Eun Yoon, et al.The Lancet. Oncology|May 10, 2016
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trialKei Muro, Hyun Cheol Chung, Veena Shankaran, et al.Palliative Medicine Reports|February 6, 2023
Outcomes of an Acute Palliative Care Unit at a Comprehensive Cancer Center in KoreaSi Won Lee, Jung Hye Kwon, Seung-Hoon Beom, et al.European Journal of Cancer (Oxford, England : 1990)|July 15, 2022
Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancerChang Gon Kim, Moonki Hong, Hei-Cheul Jeung, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2023
Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer StudyChoong-Kun Lee, Hyo Song Kim, Minkyu Jung, et al.JAMA Network Open|August 3, 2019
Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical TrialTakaki Yoshikawa, Kei Muro, Kohei Shitara, et al.Breast Cancer Research and Treatment|May 11, 2010
Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanesGabriel N Hortobagyi, Henry L Gomez, Rubi K Li, et al.Cancer Research and Treatment|October 5, 2018
Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical TrialMin Hwan Kim, Xianglan Zhang, Minkyu Jung, et al.Pageof 32